Duncker Streett & Co. Inc. raised its stake in Merck & Co. (NYSE:MRK) by 0.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 50,070 shares of the company’s stock after buying an additional 22 shares during the period. Merck & Co. makes up about 1.0% of Duncker Streett & Co. Inc.’s investment portfolio, making the stock its 26th largest position. Duncker Streett & Co. Inc.’s holdings in Merck & Co. were worth $2,884,000 at the end of the most recent quarter.
Other large investors have also modified their holdings of the company. Orbis Allan Gray Ltd acquired a new stake in shares of Merck & Co. during the first quarter valued at $239,761,000. NN Investment Partners Holdings N.V. acquired a new stake in shares of Merck & Co. during the first quarter valued at $174,068,000. Los Angeles Capital Management & Equity Research Inc. increased its stake in shares of Merck & Co. by 249.7% in the first quarter. Los Angeles Capital Management & Equity Research Inc. now owns 2,288,444 shares of the company’s stock valued at $121,082,000 after buying an additional 1,634,004 shares during the last quarter. OMERS ADMINISTRATION Corp purchased a new position in Merck & Co. during the first quarter valued at approximately $67,685,000. Finally, Canada Pension Plan Investment Board increased its position in Merck & Co. by 326.5% in the first quarter. Canada Pension Plan Investment Board now owns 1,626,461 shares of the company’s stock valued at $86,056,000 after buying an additional 1,245,129 shares during the last quarter. Hedge funds and other institutional investors own 72.92% of the company’s stock.
Merck & Co. (NYSE:MRK) traded down 0.10% on Friday, reaching $62.96. The company’s stock had a trading volume of 7,679,801 shares. The stock has a market capitalization of $174.10 billion, a P/E ratio of 34.54 and a beta of 0.63. Merck & Co. has a 52 week low of $47.97 and a 52 week high of $64.00. The firm has a 50 day moving average price of $62.85 and a 200 day moving average price of $57.69.
Merck & Co. (NYSE:MRK) last issued its quarterly earnings data on Friday, July 29th. The company reported $0.93 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.91 by $0.02. Merck & Co. had a net margin of 13.01% and a return on equity of 23.41%. The business earned $9.84 billion during the quarter, compared to analysts’ expectations of $9.79 billion. During the same period last year, the company posted $0.86 EPS. The company’s revenue was up .6% on a year-over-year basis. On average, equities analysts anticipate that Merck & Co. will post $3.75 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Friday, October 7th. Shareholders of record on Thursday, September 15th will be paid a $0.46 dividend. The ex-dividend date is Tuesday, September 13th. This represents a $1.84 annualized dividend and a yield of 2.92%. Merck & Co.’s payout ratio is currently 101.10%.
Several research firms have commented on MRK. Argus restated a “buy” rating and set a $65.00 price objective on shares of Merck & Co. in a report on Wednesday, September 14th. Morgan Stanley set a $60.00 price objective on Merck & Co. and gave the stock a “hold” rating in a research report on Tuesday, September 13th. Jefferies Group reissued a “hold” rating and issued a $56.00 price objective (down previously from $57.00) on shares of Merck & Co. in a research report on Monday, September 12th. Berenberg Bank reissued a “hold” rating and issued a $62.00 price objective on shares of Merck & Co. in a research report on Sunday, September 11th. Finally, Barclays PLC raised their price objective on Merck & Co. from $66.00 to $72.00 and gave the stock an “overweight” rating in a research report on Friday, September 9th. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating and nine have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of €63.20 ($70.23).
In other Merck & Co. news, EVP Adam H. Schechter sold 39,200 shares of Merck & Co. stock in a transaction on Thursday, September 1st. The shares were sold at an average price of €62.61 ($69.57), for a total value of €2,454,312.00 ($2,727,013.33). Following the transaction, the executive vice president now owns 39,200 shares in the company, valued at approximately €2,454,312 ($2,727,013.33). The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Weir Mirian M. Graddick sold 30,000 shares of Merck & Co. stock in a transaction on Friday, July 1st. The shares were sold at an average price of €57.49 ($63.88), for a total transaction of €1,724,700.00 ($1,916,333.33). Following the completion of the transaction, the insider now owns 162,151 shares in the company, valued at approximately €9,322,060.99 ($10,357,845.54). The disclosure for this sale can be found here. 0.05% of the stock is currently owned by company insiders.
About Merck & Co.
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It operates through one segment, Pharmaceutical. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co. (NYSE:MRK).
Receive News & Ratings for Merck & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. and related companies with MarketBeat.com's FREE daily email newsletter.